At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 332 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD)
In Brief
A Phase 4 clinical trial evaluating Ranibizumab for Neovascular Age-related Macular Degeneration. Completed, enrolled 332 participants across 23 sites.
Detailed Summary
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartFeb 2013
Primary CompletionNov 2015
TodayJul 2026
First PostedJan 24, 2013
Enrollment StartFeb 22, 2013
Primary CompletionNov 23, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.4 years ago
Interventions
Ranibizumabdrug
Intravitreal injections of 0.5 mg Ranibizumab